APA (7th ed.) Citation

F, D., R, R., C, C., G, M., S, U., R, A., . . . A, C. (2021). Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Annals of hematology, 100(9), 2325. https://doi.org/10.1007/s00277-021-04534-8

Chicago Style (17th ed.) Citation

F, Davies, et al. "Real-world Comparative Effectiveness of Triplets Containing Bortezomib (B), Carfilzomib (C), Daratumumab (D), or Ixazomib (I) in Relapsed/refractory Multiple Myeloma (RRMM) in the US." Annals of Hematology 100, no. 9 (2021): 2325. https://doi.org/10.1007/s00277-021-04534-8.

MLA (9th ed.) Citation

F, Davies, et al. "Real-world Comparative Effectiveness of Triplets Containing Bortezomib (B), Carfilzomib (C), Daratumumab (D), or Ixazomib (I) in Relapsed/refractory Multiple Myeloma (RRMM) in the US." Annals of Hematology, vol. 100, no. 9, 2021, p. 2325, https://doi.org/10.1007/s00277-021-04534-8.